Cyclobenzaprine Production Cost Reports

The report provides detailed analysis essential for establishing a cyclobenzaprine production plant. It encompasses all critical aspects necessary for cyclobenzaprine production, including the cost of cyclobenzaprine production, cyclobenzaprine plant cost, cyclobenzaprine production costs, and the overall cyclobenzaprine production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a cyclobenzaprine production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Cyclobenzaprine Market Analysis: Demand and Supply Analysis, and Sourcing

Cyclobenzaprine is a muscle relaxant with a chemical structure similar to that of tricyclic antidepressants. Hoffmann-La Roche first developed it in 1961 while working on antidepressant drugs, but it was not successful for that purpose. Its structure differs from amitriptyline by one double bond, which helps explain its effects and safety warnings. It was approved in the United States in 1977 and sold under the Flexeril brand, followed later by Fexmid and Amrix. Doctors use it to treat muscle spasms linked to acute back pain, neck strain, sports injuries, whiplash, and recovery after surgery. It became one of the most widely used muscle relaxants. It is available in tablets, capsules, sublingual films, and compounded forms.

Cyclobenzaprine is supplied by several generic manufacturers. Medichem and Derivados Quimicos supply the active ingredient from Spain, while Hetero, Unichem Laboratories, Jubilant Biosys, and Vasudha Pharma Chem supply it from India. Most of these manufacturers have United States Drug Master Files (DMFs), which support their entry into the American generic drug market. A cyclobenzaprine demand and supply analysis considers prescription volumes for muscle and joint conditions, short treatment periods, the demand for immediate-release and extended-release products, falling generic prices, and the number of approved suppliers. Delivery times, minimum order quantities, regulatory filing coverage, and audit records also influence supply agreements.

Cyclobenzaprine has high prescription demand but requires relatively small amounts of active ingredient. Treatment usually lasts no more than two to three weeks because longer-term benefits have not been established. As a result, each prescription uses only a small amount of the drug, measured in milligrams rather than grams. Immediate-release tablets in 5 mg and 10 mg strengths account for most demand, while extended-release capsules in 15 mg and 30 mg strengths offer a more convenient option for some patients. Pharmacies, hospitals, clinics, and mail-order services stock immediate-release products. Research into fibromyalgia has also led to the development of sublingual forms. These products differ in dose, release rate, onset of action, duration, and the risk of daytime drowsiness. Buyers consider price, impurity levels, regulatory filings, audit records, supply reliability, and flexibility in batch sizes.

Summary of the Product, Grades, and Uses

Cyclobenzaprine is sold as the hydrochloride salt, with the free base carrying CAS number 303-53-7 and the salt carrying 6202-23-9. The base has the molecular formula C20H21N and a molecular weight of 275.39, while the salt is C20H21N·HCl at 311.85. The chemical name is 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride, and the EINECS number is 206-145-8. The solid is a white crystalline material melting near 216 to 218 degree Celsius, with a pKa of 8.47 at 25 degree Celsius. Alkaline aqueous solutions release the free base, which matters in both analysis and formulation. Appearance, melting range, water content, residual solvents, and assay are the routine checks.

Cyclobenzaprine solubility explains why the salt is the commercial form. The hydrochloride is very soluble in water at above 20 grams in 100 milliliters, freely soluble in methanol and ethanol, sparingly soluble in isopropanol & practically insoluble in hydrocarbons. That isopropanol behavior, neither too soluble nor too insoluble, is exactly what makes it the crystallization solvent of choice. Ultraviolet maxima sit at 226 and 295 nanometers for the salt. The free base boils at 175 to 180 degree Celsius under one millimeter of mercury, so it is never isolated as a dry solid in commercial practice. Particle size, bulk density, flow, and color are set at the final crystallization.

Cyclobenzaprine active ingredient is supplied to a single pharmacopoeial standard. Content runs between 98.0 and 102.0 percent on the dried basis, measured against a reference standard, with related compounds A and B controlled by their own standards. Finished products include immediate-release tablets at 5 and 10 mg, extended-release capsules at 15 and 30 mg & a sublingual tablet studied in fibromyalgia. Extended-release capsules use sugar spheres, ethylcellulose, diethyl phthalate, gelatin, coating polymer & titanium dioxide with colorants. The release profile, not the molecule, is what separates those products. Sugar spheres, coating thickness, polymer ratio, and curing conditions build that profile.

Main End-Uses of Cyclobenzaprine

Cyclobenzaprine is prescribed as an adjunct to rest and physical therapy for muscle spasm in acute painful musculoskeletal conditions. Labels limit use to two or three weeks in adults, in acute cases, since evidence of benefit beyond that period was never established. Immediate release dosing runs 5 to 10 mg three times a day, while the extended-release capsule gives 15 mg once daily with 30 mg available where needed. Capsule contents may be sprinkled on a tablespoon of applesauce, which is bioequivalent to swallowing the capsule whole. The drug does nothing for spasticity from cerebral or spinal cord disease. Back strain, neck strain, muscle injury, and post-operative spasm are the real targets.

Cyclobenzaprine works centrally rather than at the muscle itself. Action sits at the brainstem level, not at the muscle, not at the spinal cord, and the molecule behaves as a serotonin 2 receptor antagonist. Oral bioavailability runs near 55 percent, protein binding near 93 percent & the immediate release half life near 18 hours. The extended release capsule stretches that to about 32 hours, with peak concentration at 7 to 8 hours and roughly two and a half fold accumulation at steady state. Metabolism runs through CYP3A4 and CYP1A2 with a smaller CYP2D6 contribution, and glucuronides leave in the urine. Age, liver function, interacting drugs, and dose all shift that exposure.

Cyclobenzaprine has also been developed into a bedtime sublingual product for fibromyalgia. That route avoids first-pass metabolism and changes the exposure profile without changing the molecule. Research laboratories buy small quantities for receptor and metabolism work. Reference standards for the drug and its two named related compounds support every release test run on the active ingredient. Those quantities are tiny next to the generic tablet trade. Universities, contract laboratories, quality units, and formulation groups make up that demand.

Cyclobenzaprine Market Risks

Cyclobenzaprine carries the cardiovascular caution that comes with any tricyclic structure. Arrhythmias, tachycardia, palpitations & conduction prolongation all appear in the labeling, and the drug is contraindicated in recovery from acute myocardial infarction, in arrhythmias, in heart block, in heart failure & in hyperthyroidism. Combination with a monoamine oxidase inhibitor is barred, before or after, within fourteen days either way. Serotonin syndrome has been reported with several antidepressant classes, tramadol, meperidine, bupropion & others. Elderly patients and those with liver impairment face higher exposure, and use in both groups is discouraged. Exposure rises about 40 percent in the elderly, with the half-life stretching toward 50 hours.

Cyclobenzaprine competes mainly on price because it has been available as a generic drug for many years. Tender prices and pharmacy substitution influence market costs. Prescribing patterns have also changed with the use of opioid-reduction policies, which have affected treatment guidelines, hospital drug lists, and prescription reviews. Muscle relaxants are also closely monitored under these policies. Extended-release and sublingual forms aim to stand out from standard products, but developing them requires extra investment. Active ingredient suppliers face strong competition from several manufacturers with regulatory filings. Buyers choose suppliers based on price, service, documentation, and reliable delivery.

Cyclobenzaprine Production Process and Main Cost Drivers

The cyclobenzaprine production process runs from 5-dibenzosuberenone and 3-dimethylaminopropyl chloride through Grignard formation, carbonyl addition, acid-promoted dehydration, neutralization, extraction, salt formation, crystallization, and drying.

1. By Grignard Addition to 5-Dibenzosuberenone and In Situ Acid Dehydration: The main inputs are 5-dibenzosuberenone, 3-dimethylaminopropyl chloride, magnesium turnings, tetrahydrofuran, hydrochloric acid, sodium carbonate, methylene dichloride, isopropanol & isopropanolic hydrogen chloride.

Cyclobenzaprine synthesis is a Grignard reaction followed by a dehydration, run in one sequence. Magnesium is warmed in tetrahydrofuran to 45 to 55 degree Celsius, and 3-dimethylaminopropyl chloride in tetrahydrofuran is added dropwise over a couple of hours to form the organomagnesium reagent. That reagent is cooled to 0 to 5 degree Celsius, and 5-dibenzosuberenone in tetrahydrofuran is charged below 10 degree Celsius, then stirred for 45 minutes at 10 to 15 degree Celsius. Addition gives the tertiary carbinol, which older routes isolated and recrystallized before dehydrating it separately. Charge order, temperature, stirring, and addition time all shape the yield of that step. The modern process skips that isolation entirely. One pot, three stages, fewer solvents.

Cyclobenzaprine forms when the carbinol loses water under acid. A quench with 20 percent aqueous hydrochloric acid followed by heating to 70 to 80 degree Celsius for three hours drives the dehydration in the same vessel. Neutralization with sodium carbonate, extraction into methylene dichloride & solvent removal give the free base as a residue. That residue is dissolved in isopropanol and acidified with isopropanolic hydrogen chloride, then held at 0 to 5 degree Celsius for two hours to crystallize the salt. Recrystallization from isopropanol and drying give white crystalline material at 78 percent yield and 99.93 percent purity. Filtration rate, cake washing, drying temperature, and milling finish the sequence.

Main Factors Affecting Cyclobenzaprine Production Cost

Cyclobenzaprine production costs mainly depend on the tricyclic ketone used in the process. 5-Dibenzosuberenone is a specialty intermediate rather than a common raw material, and about one mole is needed for each mole of cyclobenzaprine produced. 3-Dimethylaminopropyl chloride is the second major input. It is usually supplied as a hydrochloride salt, which is converted into its free form before use. Magnesium, hydrochloric acid, sodium carbonate, water, and isopropanol cost much less in comparison. A plant that produces its own 5-dibenzosuberenone from dibenzosuberone-based intermediates can reduce raw material costs and retain more profit. Freight, import duties, storage, insurance, and working capital add to the overall purchase cost.

Cyclobenzaprine production costs depend mainly on the Grignard reaction and solvent recovery. The reaction requires moisture-free conditions, controlled starting conditions, a steady rate of adding materials, and careful heat control. Moisture can destroy the reagent, while delayed reaction initiation can cause a sudden and dangerous release of heat. Tetrahydrofuran and methylene dichloride are recovered and reused, helping reduce utility and material costs. Crystallization using isopropanol helps achieve a final purity of 99.9% under well-controlled conditions. A one-pot process with a yield of 78% gives better results than the older three-stage method. Each batch also requires laboratory testing for two specified related compounds. These tests require reference standards, checks to confirm that the testing system works correctly, validated methods, and regular monitoring of results.

Raw Materials for Cyclobenzaprine Production Plant and its Procurement

Cyclobenzaprine raw material procurement is short, specialized & concentrated in one intermediate. 5-Dibenzosuberenone comes from a limited group of fine chemical makers, and qualification of a second source takes months. 3-Dimethylaminopropyl chloride is bought as the salt, since the free amine is unstable, and it is liberated in situ. Magnesium turnings are specified for particle size and surface condition, both of which affect Grignard initiation. Tetrahydrofuran, methylene dichloride, isopropanol, sodium carbonate & hydrochloric acid complete the list.

Cyclobenzaprine plants test raw materials before use because the Grignard reaction requires careful control. Tetrahydrofuran is checked for water and peroxides before being added to a reactor, as both can affect the reaction. Magnesium is inspected for quality and particle size and may be treated to help the reaction start properly. 5-Dibenzosuberenone is tested for related ketones that could remain as impurities in the final product. Solvents are purchased in pharmaceutical grades to meet residual solvent limits without extra processing. Each solvent drum is checked for water content, peroxide levels, purity, and color.

Sustainability and Regulatory Requirements

Cyclobenzaprine is manufactured under pharmaceutical Good Manufacturing Practices (GMP) and must meet the required pharmacopoeial standards. The main purity requirement is 98.0 to 102.0% on a dried basis, with limits for two specified related compounds. Exporters supplying the United States maintain Drug Master Files (DMFs), while Indian manufacturers provide written confirmations for supplies to Europe. Safety documents cover the Grignard reaction, which is the main hazard in the manufacturing process. Any change to the process requires updates to the regulatory file and safety assessment. Plants also maintain batch records, document deviations, control changes, conduct annual reviews, and prepare for inspections.

Cyclobenzaprine plants produce waste similar to other solvent-based chemical plants. Water-based liquids from quenching and neutralization contain chloride and sodium salts, so they must be treated in an effluent treatment plant before disposal. Methylene dichloride is recovered through distillation, while the remaining waste is sent for incineration under the rules for halogenated waste. Tetrahydrofuran, isopropanol, and washing liquids are also recovered and reused when their quality is suitable. Magnesium salts from the quenching stage add to the salt content of wastewater, which the treatment plant must handle. Plants track energy and water use, solvent losses, and waste quantities during each production cycle.

CAPEX and OPEX for a Cyclobenzaprine Production Plant

The cyclobenzaprine plant setup cost suits a standard multipurpose block with Grignard capability. Glass-lined or stainless reactors of a few thousand liters cover reagent formation, addition & dehydration, with jacket cooling sized for the exotherms. Nitrogen inerting, moisture exclusion, dosing control, temperature trending & emergency quench capability are the features that distinguish a Grignard-capable plant. Downstream equipment covers extraction vessels, phase separators, solvent recovery columns, crystallizers, centrifuges or filter dryers, a mill & a packing room. Quality control needs chromatography, water determination, residual solvent analysis, assay & melting point capability.

Cyclobenzaprine operating cost is material-led, with solvent recovery close behind. The suberenone intermediate dominates the material line, with the aminopropyl chloride second and everything else trailing. Utilities carry steam, chilled brine for the cold addition, vacuum, nitrogen, cooling water & distillation duty. Labor covers operators, chemists, engineers, quality assurance & regulatory staff in the usual ratio. Campaign length matters, since changeover cleaning in a multipurpose block consumes days. Depreciation is modest where the Grignard capability is shared across several products. Insurance, calibration, maintenance, monitoring, and waste disposal round out the fixed side.

Plant Location and Investment Factors

Cyclobenzaprine production requires standard fine chemical manufacturing skills rather than special raw materials. Spain has two established manufacturers with United States regulatory filings that supply customers in Europe and the United States. India has the largest group of qualified manufacturers, including companies based in Hyderabad and Mumbai. China supplies tricyclic intermediates, solvents, and other chemicals used in production. Finished tablets and capsules are often manufactured close to the markets where they are sold because they are easy to transport. However, companies must meet the regulatory requirements of each market. Skilled chemists, wastewater treatment facilities, valid permits, and access to ports also influence plant location.

Investment in cyclobenzaprine production depends on whether a company makes its own intermediates or buys them from suppliers, and whether it can share equipment with other products. Buying 5-dibenzosuberenone and producing cyclobenzaprine in one batch each year requires less investment, making this option suitable for contract manufacturers. Producing the intermediate in-house can reduce purchasing costs and shorten the supply chain, but requires extra equipment and investment. Extended-release and sublingual products require formulation skills rather than a new chemical manufacturing process. Most active ingredient manufacturers produce cyclobenzaprine as part of a wider range of generic medicines. They need to manage production schedules, shared equipment, batch sizes, and annual demand.

Major Cyclobenzaprine Producing Regions

Cyclobenzaprine production is spread across Spain, India, the United States, and China, with each country handling different parts of the supply chain. Spain has two established manufacturers, Medichem and Derivados Quimicos, both of which have Drug Master Files for the American market. India has the largest group of qualified producers, including Hetero, Unichem Laboratories, Jubilant Biosys, and Vasudha Pharma Chem. The United States handles finished drug manufacturing, distribution, and the development of sublingual products. China supplies tricyclic ketone intermediates used in production. European and American buyers source cyclobenzaprine through these established generic supply chains, with each country contributing to a different stage of production.

Key Cyclobenzaprine Producers

Medichem

• Spanish active ingredient producer serving regulated markets from European sites.
• Supplies cyclobenzaprine hydrochloride with a United States drug master file on file.
• Competes on European manufacturing standards, documentation, regulatory coverage & customer support.
• Serves generic formulators across Europe and North America.

Derivados Quimicos

• Spanish fine chemical and active ingredient manufacturer.
• Offers the active ingredient under good manufacturing practice with American regulatory filings.
• Competes on process control, inspection records, quality systems & European supply security.
• Holds both a drug master file and regulatory coverage for the United States market.

Unichem Laboratories

• Indian pharmaceutical company with active ingredient and finished dose operations.
• Produces cyclobenzaprine hydrochloride for export with a United States filing.
• Competes on Indian cost base, integrated capability, scale & regulatory experience.
• Supplies formulators in regulated and semi-regulated markets alike.

Vasudha Pharma Chem

• Indian active ingredient maker based in the Hyderabad cluster.
• Supplies the molecule with a United States drug master file supporting generic filings.
• Competes on pricing, campaign flexibility, intermediate integration & delivery record.
• Serves generic manufacturers across several regions.

Hetero

• Large Indian generic group with wide active ingredient and formulation capacity.
• Lists cyclobenzaprine hydrochloride among its filed active ingredients.
• Competes on scale, vertical integration, cost & breadth of regulatory filings.
• Runs active ingredient capacity alongside its own finished dose business.

Tonix Pharmaceuticals

• American company developing a bedtime sublingual form of the molecule.
• Studied that form in late-stage trials for fibromyalgia rather than muscle spasm.
• Competes on delivery route, clinical data & a repositioned indication.
• Works from the same active ingredient the generic market already supplies.